Amgen, Inc. vs Toronto-Dominion Bank — how do they compare? Amgen, Inc. trades at $412.21 (market cap $225.71B), while Toronto-Dominion Bank trades at $121.35 (market cap $199.91B). The key difference: Amgen, Inc. and Toronto-Dominion Bank are close in size by market cap, and Toronto-Dominion Bank pays the higher dividend (2.64%). Which is the better fit depends on your goals.
| AMGN | TD | |
|---|---|---|
Market Cap | $225.71B | $199.91B |
Sector | Health | Financials |
52-Week High | $417.20 | $124.80 |
52-Week Low | $271.18 | $72.85 |
Enterprise Value | $269.02B | — |
Dividend Yield | 2.42% | 2.64% |
Trailing returns across standard periods
Latest headlines on both assets
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →Toronto-Dominion is one of Canada's two largest banks and operates three business segments: Canadian retail banking, U.S. retail banking, and wholesale banking. The bank's U.S. operations span from Maine to Florida, with a strong presence in the Northeast. It also has a 13% ownership stake in Charles Schwab.
Read more on TD →